Dirk Haasner - Ovid Therapeutics Senior Vice President - Global Regulatory Affairs
| OVID Stock | USD 1.05 0.01 0.94% |
President
Dr. Dirk Haasner, Ph.D., MPM serves as Senior Vice President Global Regulatory Affairs of the Company since March 2016. Dr. Haasner has served as our Senior Vice President, Global Regulatory Affairs since March 2016. Dr. Haasner previously served as our Vice President, Global Regulatory Affairs from December 2015 to March 2016. Prior to joining us, Dr. Haasner was Vice President Regulatory and Medical Affairs, and Vice President Regulatory Strategy and Policy at Lundbeck USA, Inc., a H. Lundbeck AS subsidiary, from February 2002 to November 2015, with responsibility for all FDA interactions on several marketed orphan drugs and all Lundbeck development compounds. From 1994 to 2002, Dr. Haasner was employed at F. HoffmannLa Roche AG, a publicly held healthcare company, where he held positions of increasing responsibility in global product development and global strategic marketing before being appointed Global Lifecycle Leader. Dr. Haasner cofounded the biotech startup 4Antibody AG that was acquired in 2014 by Agenus Inc., a publicly held biotechnology company since 2016.
| Age | 59 |
| Tenure | 8 years |
| Address | 41 Ninth Avenue, New York, NY, United States, 10001 |
| Phone | 646 661 7661 |
| Web | https://www.ovidrx.com |
Ovid Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3604) % which means that it has lost $0.3604 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3661) %, meaning that it created substantial loss on money invested by shareholders. Ovid Therapeutics' management efficiency ratios could be used to measure how well Ovid Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 23, 2024, Return On Tangible Assets is expected to decline to -0.38. In addition to that, Return On Capital Employed is expected to decline to -0.47. At present, Ovid Therapeutics' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Intangibles To Total Assets is expected to grow to 0, whereas Net Tangible Assets are forecasted to decline to about 81.7 M.Similar Executives
| Found 5 records | PRESIDENT Age | ||
| David JD | Connect Biopharma Holdings | 50 | |
| Leslie Robbins | CytomX Therapeutics | N/A | |
| Wubin MBA | Connect Biopharma Holdings | 59 | |
| David Szekeres | Connect Biopharma Holdings | 50 | |
| Timothy Keutzer | Spero Therapeutics | 56 | |
Management Performance
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.36 |
Ovid Therapeutics Leadership Team
Elected by the shareholders, the Ovid Therapeutics' board of directors comprises two types of representatives: Ovid Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ovid. The board's role is to monitor Ovid Therapeutics' management team and ensure that shareholders' interests are well served. Ovid Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ovid Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Meg Alexander, Chief Officer | ||
| Claude MD, Head RD | ||
| SPHR SHRMSCP, VP Facilities | ||
| Jason MBA, Chief Officer | ||
| Lora Pike, Senior Relations | ||
| Dirk Haasner, Senior Vice President - Global Regulatory Affairs | ||
| MBA JD, General Counsel | ||
| Simon Kelner, Chief Officer | ||
| Zoology Dphil, CEO Pres | ||
| Julia Tsai, Senior Development | ||
| Tom Parry, Vice Development | ||
| Toshiya DVM, Head Research | ||
| Zhong Zhong, Chief Officer | ||
| Manoj MD, Chief Officer | ||
| DSc FACP, Founder Board | ||
| Jeffrey Rona, Principal Officer | ||
| MPH MD, Senior Affairs |
Ovid Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ovid Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.36 | ||||
| Operating Margin | (76.45) % | ||||
| Current Valuation | 27.63 M | ||||
| Shares Outstanding | 71.01 M | ||||
| Shares Owned By Insiders | 15.89 % | ||||
| Shares Owned By Institutions | 56.45 % | ||||
| Number Of Shares Shorted | 679.89 K | ||||
| Price To Earning | 1.11 X | ||||
| Price To Book | 0.99 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ovid Therapeutics is a strong investment it is important to analyze Ovid Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ovid Therapeutics' future performance. For an informed investment choice regarding Ovid Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ovid Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For information on how to trade Ovid Stock refer to our How to Trade Ovid Stock guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ovid Therapeutics. If investors know Ovid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ovid Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.46) | Revenue Per Share 0.009 | Quarterly Revenue Growth 0.587 | Return On Assets (0.36) | Return On Equity (0.37) |
The market value of Ovid Therapeutics is measured differently than its book value, which is the value of Ovid that is recorded on the company's balance sheet. Investors also form their own opinion of Ovid Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Ovid Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ovid Therapeutics' market value can be influenced by many factors that don't directly affect Ovid Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ovid Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ovid Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ovid Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.